Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $17.30.
A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Tuesday. Evercore ISI assumed coverage on shares of Vir Biotechnology in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research note on Monday, September 15th. Raymond James Financial assumed coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They set an “outperform” rating on the stock. Finally, Bank of America upgraded shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $12.00 to $14.00 in a research note on Wednesday, August 27th.
Get Our Latest Report on Vir Biotechnology
Insider Activity
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ARCH Venture Management LLC acquired a new position in Vir Biotechnology during the second quarter worth about $65,100,000. Orbimed Advisors LLC lifted its holdings in shares of Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock valued at $11,999,000 after purchasing an additional 132,466 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vir Biotechnology by 9.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company’s stock valued at $8,909,000 after purchasing an additional 122,219 shares in the last quarter. Aberdeen Group plc lifted its holdings in shares of Vir Biotechnology by 45.3% in the second quarter. Aberdeen Group plc now owns 1,006,891 shares of the company’s stock valued at $5,075,000 after purchasing an additional 313,699 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Vir Biotechnology Stock Performance
NASDAQ VIR opened at $5.72 on Wednesday. Vir Biotechnology has a one year low of $4.16 and a one year high of $14.45. The firm’s fifty day moving average is $5.08 and its two-hundred day moving average is $5.28. The firm has a market cap of $794.62 million, a PE ratio of -1.43 and a beta of 1.27.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The firm had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.38 million. During the same quarter last year, the firm earned ($1.02) earnings per share. The company’s revenue was down 60.5% compared to the same quarter last year. Research analysts predict that Vir Biotechnology will post -3.92 earnings per share for the current year.
About Vir Biotechnology
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Read More
- Five stocks we like better than Vir Biotechnology
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- How to trade penny stocks: A step-by-step guide
- Buyback Boom: 3 Companies Betting Big on Themselves
- What is a Secondary Public Offering? What Investors Need to Know
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.